Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions - PubMed (original) (raw)
Review
. 2016 Aug;75(8):1428-37.
doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3.
Affiliations
- PMID: 27261493
- DOI: 10.1136/annrheumdis-2016-209201
Free article
Review
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Georg Schett et al. Ann Rheum Dis. 2016 Aug.
Free article
Abstract
Improvements in the control of inflammation in rheumatoid arthritis (RA) by conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) have led to a substantial change in the clinical outcomes of patients during the last 30 years. Current treatment can lead to sustained remission in some patients raising questions about the optimal management strategies in this subgroup of patients. Today, tapering of DMARDs and even their discontinuation appears as an interesting concept for achieving a more tailored and dynamic treatment approach of RA, especially in patients, who achieved full disease control by DMARD treatment. In this review article, current developments of DMARD tapering are discussed. The article provides an overview of existing studies on this topic and addresses new strategies to reach drug-free remission. Furthermore, concepts for defining patients eligible for DMARD tapering are described and potential future strategies in using biomarkers in predicting the risk for disease relapse after initiation of DMARD tapering are addressed. These findings are finally considered in light of the vision to achieve cure as an ultimate goal in patients with RA achieving full control of inflammation.
Keywords: DMARDs (synthetic); Inflammation; Rheumatoid Arthritis.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
- Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ. Kuijper TM, et al. J Rheumatol. 2015 Nov;42(11):2012-22. doi: 10.3899/jrheum.141520. Epub 2015 Oct 1. J Rheumatol. 2015. PMID: 26428204 Review. - Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE, Sundlisæter NP, Aga AB, Sexton J, Olsen IC, Fremstad H, Spada C, Madland TM, Høili CA, Bakland G, Lexberg Å, Hansen IJW, Hansen IM, Haukeland H, Ljoså MA, Moholt E, Uhlig T, Kvien TK, Solomon DH, van der Heijde D, Haavardsholm EA, Lillegraven S. Kjørholt KE, et al. Lancet Rheumatol. 2024 May;6(5):e268-e278. doi: 10.1016/S2665-9913(24)00021-3. Epub 2024 Apr 4. Lancet Rheumatol. 2024. PMID: 38583450 Clinical Trial. - Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Wendler J, Schuch F, Ronneberger M, Lorenz HM, Nuesslein H, Alten R, Demary W, Henes J, Schett G, Rech J. Haschka J, et al. Ann Rheum Dis. 2016 Jan;75(1):45-51. doi: 10.1136/annrheumdis-2014-206439. Epub 2015 Feb 6. Ann Rheum Dis. 2016. PMID: 25660991 Clinical Trial. - Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Betts KA, et al. Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2. Clin Ther. 2016. PMID: 27045991 - Current concepts in the management of rheumatoid arthritis.
Tanaka Y. Tanaka Y. Korean J Intern Med. 2016 Mar;31(2):210-8. doi: 10.3904/kjim.2015.137. Epub 2016 Feb 26. Korean J Intern Med. 2016. PMID: 26932398 Free PMC article. Review.
Cited by
- The Role of Natural Products in Rheumatoid Arthritis: Current Knowledge of Basic In Vitro and In Vivo Research.
Deligiannidou GE, Gougoula V, Bezirtzoglou E, Kontogiorgis C, Constantinides TK. Deligiannidou GE, et al. Antioxidants (Basel). 2021 Apr 13;10(4):599. doi: 10.3390/antiox10040599. Antioxidants (Basel). 2021. PMID: 33924632 Free PMC article. Review. - Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.
Raghunath S, Hijjawi R, Hoon E, Shanahan EM, Goldblatt F. Raghunath S, et al. Clin Rheumatol. 2019 Oct;38(10):2699-2707. doi: 10.1007/s10067-019-04609-y. Epub 2019 Jun 6. Clin Rheumatol. 2019. PMID: 31172365 - Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T; SURPRISE study group. Kaneko Y, et al. Ann Rheum Dis. 2018 Sep;77(9):1268-1275. doi: 10.1136/annrheumdis-2018-213416. Epub 2018 May 31. Ann Rheum Dis. 2018. PMID: 29853455 Free PMC article. Clinical Trial. - Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Lexberg ÅS, Madland TM, Fremstad H, Høili CA, Bakland G, Spada C, Haukeland H, Hansen IM, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA. Lillegraven S, et al. Ann Rheum Dis. 2023 Nov;82(11):1394-1403. doi: 10.1136/ard-2023-224476. Epub 2023 Aug 22. Ann Rheum Dis. 2023. PMID: 37607809 Free PMC article. Clinical Trial. - Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights.
Janakiraman K, Krishnaswami V, Rajendran V, Natesan S, Kandasamy R. Janakiraman K, et al. Mater Today Commun. 2018 Dec;17:200-213. doi: 10.1016/j.mtcomm.2018.09.011. Epub 2018 Sep 15. Mater Today Commun. 2018. PMID: 32289062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical